Cord Blood News Volume 5.20 | May 23 2013

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16x33 Bispecific Killer Cell Engager (BiKE) and ADAM17 Inhibition
Scientists determined whether a novel BiKE signaling through CD16 and targeting CD33 could activate natural killer (NK) cells at high potency against acute myeloid leukemia targets. Treatment of NK cells from double umbilical cord blood transplant recipients with the CD16x33 BiKE resulted in activation, especially in those recipients with CMV reactivation. [Clin Cancer Res] Abstract

Canonical Transient Receptor Potential 3 Channel Triggers VEGF-Induced Intracellular Ca²⁺ Oscillations in Endothelial Progenitor Cells Isolated from Umbilical Cord Blood
Researchers investigated whether the higher proliferative potential of umbilical cord blood-derived endothelial colony forming cells was associated to any difference in the molecular underpinnings of their Ca²⁺ response to VEGF. [Stem Cell Dev] Abstract

Mesenchymal Stromal Cell Characteristics Vary Depending on Their Origin
Investigators evaluated mesenchymal stromal cells (MSCs) derived from perinatal tissues umbilical cord and amniotic membrane in comparison to adult MSCs from bone marrow which were used as gold standard. [Stem Cells Dev] Abstract

Successful Short-Term Cryopreservation of Volume-Reduced Cord Blood Units in a Cryogenic Mechanical Freezer: Effects on Cell Recovery, Viability, and Clonogenic Potential
Scientists examined the effects of cryostorage in a mechanical freezer at -150°C on critical quality control variables of cord blood collections to investigate the possible use of mechanical freezers at -150°C as an alternative to storage in liquid- (or vapor-) phase nitrogen. [Transfusion] Abstract

A Synthetic Formulation, Dhanwantharam Kashaya, Delays Senescence in Stem Cells
Investigators evaluated the effects of Dhanwantram kashaya on the proliferation, viability and senescence of human wharton jelly mesenchymal stem cells in vitro. [Cell Prolif] Abstract

Relative Biological Efficiency of Protons at Low and Therapeutic Doses in Induction of 53BP1/γH2AX Foci in Lymphocytes from Umbilical Cord Blood
In order to evaluate DNA damage induced by protons at low and radiotherapeutic doses, lymphocytes from umbilical cord blood of the same four probands were irradiated in the dose range of 1-200 cGy with γ-rays and protons. [Int J Radiat Biol] Abstract

CD271 as a Marker for Mesenchymal Stem Cells in Bone Marrow versus Umbilical Cord Blood
The authors examined the potential application of CD271 as a marker for the isolation of mesenchymal stem cells from umbilical cord blood. [Cells Tissues Organs] Abstract

Growth of Erythroid Cells from Thawed Unseparated Cord Blood In Vitro without Exogenous Erythropoietin
Previous erythroid cell cultures have depended on added serum or erythropoietin. Here, the growth of erythroid cells from thawed unseparated cord blood units in vitro without serum or exogenous erythropoietin is reported. [Transfus Apher Sci] Abstract

Cord Blood America, Inc. Announces New Service Offering
Cord Blood America, Inc. announced the launch of a new service offering for the storage of mesenchymal cells through its wholly owned subsidiary CorCell Companies, Inc. [Cord Blood America, Inc.] Press Release

Maryland Stem Cell Research Commission Funds 31 New Research Proposals in FY 2013
The Maryland Stem Cell Research Commission has completed its review of the 171 applications received in response to its FY 2013 Requests for Applications. The board of directors of the Maryland Technology Development Corporation approved the Commission’s recommendation to fund 31 new proposals with the Maryland Stem Cell Research Fund’s $10.4 million FY2013 budget. [Maryland Stem Cell Research Fund] Press Release

NIH Saves Lives: Fred Hutchinson Cancer Research Center Calls on Congress to Restore Full NIH Funding
Fred Hutchinson Cancer Research Center called on Congress to support restoring full funding to the National Institutes of Health (NIH), which supports pioneering research that saves lives. Funding was recently cut due to sequestration. [Fred Hutchinson Cancer Research Center] Press Release

Title21 Software’s Cell Therapy Solution Chosen by Reputable Umbilical Cord Blood Bank
Title21 Software announced that Cleveland Cord Blood Center has selected Title21 Software’s Cell Therapy Solution to automate their cord blood facility. Cleveland Cord Blood Center will streamline their quality management processes, document control and training management with Title21 Software’s integrated electronic solution. [Title21 Software, Inc.] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Postdoctoral Researcher – Hematopoietic Stem Cells (Albert Einstein College of Medicine)

Assistant Professor – Stem Cell Transplantation (Boston Children’s Hospital/Harvard Medical School)

Postdoctoral Fellow – Stem Cell and Cancer Biology (Johns Hopkins University School of Medicine)

Postdoctoral Research Scientist (Anthony Nolan)

Research Associate (University of Texas Southwestern Medical Center at Dallas)

Postdoctoral Position – Novel Gene Discovery (St. Jude Children’s Research Hospital)

Postdoctoral Position – Stem Cell Biology (St. Jude Children’s Research Hospital)

Technology Manager (GE Healthcare)

Development/Senior Development Scientist (GE Healthcare)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.